Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Share News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 380.00
Bid: 374.00
Ask: 386.00
Change: 0.00 (0.00%)
Spread: 12.00 (3.209%)
Open: 380.00
High: 380.00
Low: 380.00
Prev. Close: 380.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MaxCyte Shares Rise As It Expects To Report 30% Increase In Revenue

Mon, 20th Jan 2020 09:00

(Alliance News) - MaxCyte Inc said Monday trading was ahead of market expectations in 2019 as revenue rose and five new clinical-commercial licenses were signed.

MaxCyte shares were trading 10% higher in London at 133.80 pence each on Monday.

In a trading update for the year ended December 31, the cell-based medicines and life sciences company said its revenue is expected to increase 30% to USD21.6 million compared to USD16.7 million in 2018.

The company said revenue growth accelerated in the second half, increasing approximately 36% to USD13.2 million, compared to USD9.7 million a year before.

During the first half of 2019, MaxCyte launched its next generation of instruments and disposables, ExPERT, "with positive feedback and strong interest from existing and new customers".

"2019 strong growth was supported by positive acceptance by customers of the launch of the ExPERT instruments and the start of the roll out of the company's expanded processing assembly line," the company noted.

During 019, MaxCyte said it signed five clinical-commercial licenses and now has more than 100 cell therapy programmes under license under which more than 70 are licensed for clinical use.

Chief Executive Officer Doug Doerfler said: "These clinical partnerships have delivered a record year of milestone payments for MaxCyte, and the growth in the number of partners and the advancement of their clinical programs will drive an increasing amount of development milestone payments to MaxCyte in fiscal year 2020 and beyond.

"Consequently, this will further boost our revenues over and above the momentum we have in our instruments and disposables business," Doerfler said.

By Loreta Juodagalvyte; loretajuodagalvyte@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 Feb 2021 21:38

IN BRIEF: GBP40 Million MaxCyte Subscription Ahead Of Dual Listing

IN BRIEF: GBP40 Million MaxCyte Subscription Ahead Of Dual Listing

Read more
20 Jan 2021 17:40

LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%

LONDON TRADING UPDATES: Alliance Pharma 2020 Revenue Slips By 5%

Read more
11 Jan 2021 14:51

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

UK TRADING UPDATE SUMMARY: Science Group To Beat Forecasts For 2020

Read more
23 Dec 2020 10:36

Maxcyte Core Life Sciences Business Results To Beat Expectations

Maxcyte Core Life Sciences Business Results To Beat Expectations

Read more
23 Oct 2020 16:04

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
13 Oct 2020 14:06

UK EXECUTIVE CHANGE SUMMARY: Danakali Hires Potash Mining Vet As COO

UK EXECUTIVE CHANGE SUMMARY: Danakali Hires Potash Mining Vet As COO

Read more
21 Sep 2020 16:24

IN BRIEF: MaxCyte Interim Revenue Jumps And Loss Narrows

IN BRIEF: MaxCyte Interim Revenue Jumps And Loss Narrows

Read more
14 Sep 2020 15:44

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Sep 2020 14:28

MaxCyte Hires Murphy As Finance Chief; Holtz Becomes Accounting Boss

MaxCyte Hires Murphy As Finance Chief; Holtz Becomes Accounting Boss

Read more
9 Sep 2020 09:35

MaxCyte appoints Amanda Murphy as CFO

(Sharecast News) - Life sciences company MaxCyte named Amanda Murphy as its chief financial officer on Wednesday, succeeding long-time CFO Ron Holtz.

Read more
18 Aug 2020 20:04

IN BRIEF: MaxCyte Says CARMA's Phase 1 MCY-M11 Trial Expanded

IN BRIEF: MaxCyte Says CARMA's Phase 1 MCY-M11 Trial Expanded

Read more
15 Jul 2020 13:31

MaxCyte Sees Higher Interim Revenue, Confident On Long-Term Prospects

MaxCyte Sees Higher Interim Revenue, Confident On Long-Term Prospects

Read more
8 Jul 2020 15:51

IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

Read more
7 May 2020 17:30

UK TRADING UPDATE SUMMARY: Filta Launches Covid-19 Sanitising Service

UK TRADING UPDATE SUMMARY: Filta Launches Covid-19 Sanitising Service

Read more
1 May 2020 08:54

MaxCyte Raises GBP25 Million To Fund Investments Ahead Of US IPO

MaxCyte Raises GBP25 Million To Fund Investments Ahead Of US IPO

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.